Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Jagannath S et al. – Overall survival with and without SCT was not different. Grade 3/4 adverse events included neutropenia, sensory neuropathy, neuropathic pain, and diarrhoea. Bortezomib ± dexamethasone is an effective and well–tolerated induction regimen for the frontline treatment of MM.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address